Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers

Clinical and Experimental Hypertension

Volumn 28, Issue 7, 2006, Pages 631-643

  Huber, Matthias ^a   Bolbrinker, Juliane ^a   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Glibenclamide; Olmesartan medoxomil; Pharmacokinetics; Safety

Indexed keywords

GLIBENCLAMIDE; OLMESARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VOLUNTEER;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLYBURIDE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 33750047560     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600946171     Document Type: Article

References (34)

1. Sicree R, Shaw J, Zimmet P. The global burden of diabetes. Diabetes Atlas, International Diabetes Federation, 2nd ed. 2003,15-111.
2. World Health Organization. The World Health Report. Geneva, Switzerland: World Health Organization, 2004.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
4. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26(Suppl. A):A28-A32.
5. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-291, 318.
6. Unger T, McInnes GT, Neutel JM, Bohm M. The role of olmesartan medoxomil in the management of hypertension. Drugs 2004;64:2731-2739.
7. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345-1353; discussion, 1354-1356.
8. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001;19(Suppl. 1):S49-S56.
9. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens 2003;21(Suppl. 2):S43-S46.
10. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003;23:419-430.
11. Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs Today (Barc) 2003;39(10):745-761.
12. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19(Suppl. 1):S21-S32.
13. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nature Medicine 2005;12:75-80.
14. Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetol 1997;34:239-244.
15. Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-1358.
16. Yoshida K, Kohzuki M. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Cardiovasc Drug Rev 2004;22:285-308.
17. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002;71:286-296.
18. McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S, Goldberg MR. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 1999;65:348-352.
19. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-349.
20. Matsuda A, Kuzuya T, Sugita Y, Kawashima K. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res 1983;15:425-428.
21. Sartor G, Melander A, Schersten B, Wahlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 1980;18:17-22.
22. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000;22:137-140.
23. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 2001;44:2107-2114.
24. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494.
25. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005;28:2806-2807.
26. American Diabetes Association. Standards of Medical Care in Diabetes-2006. Diabetes Care 2006;29(Suppl. 1):S4-S42.
27. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26(5):1408-1412.
28. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002;112:603-609.
29. Schmieder RE. Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. J Hypertens 2005;23:905-911.
30. Tobe SW, McFarlane PA, Naimark DM. Microalbuminuria in diabetes mellitus. CMAJ 2002;167:499-503.
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, plus the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
32. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
33. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
34. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.